LEVO-DROMORAN (levorphanol tartrate) by Bausch + Lomb is clinical pharmacology mechanism of action levorphanol is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 1953.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
LEVO-DROMORAN (levorphanol tartrate) is an oral full mu-opioid agonist indicated for severe pain requiring opioid treatment when alternatives are inadequate. It works by binding to mu-opioid receptors in the brain and spinal cord, producing analgesia without a ceiling effect, though clinical dosing is limited by adverse effects including respiratory and CNS depression.
Product approaching loss of exclusivity with minimal recent commercial data; team likely focused on cost management and retention rather than growth expansion.
CLINICAL PHARMACOLOGY Mechanism of Action Levorphanol is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of levorphanol is analgesia. Like all full opioid agonists, there…
Worked on LEVO-DROMORAN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LEVO-DROMORAN offers limited career trajectory given LOE status, minimal commercial spending, and zero linked job postings, reflecting the product's mature and declining market position. Roles available are primarily defensive—focused on compliance, generic transition, and cost containment rather than growth and innovation.